LUND, Sweden , May 21, 2024 /PRNewswire/ –. Hansa Biopharma, “Hansa” (NASDAQ: HNSA) (STOCKHOLM: HNSA), today announced data featuring imlifidase will be…
The designation is based on Phase III INAVO120 results, showing the inavolisib-based regimen more than doubled progression-free survival compared with…